Leerink Partnrs Has Strong Forecast for RARE Q2 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Analysts at Leerink Partnrs increased their Q2 2025 EPS estimates for shares of Ultragenyx Pharmaceutical in a report released on Wednesday, May 7th. Leerink Partnrs analyst J. Schwartz now expects that the biopharmaceutical company will post earnings of ($1.29) per share for the quarter, up from their prior estimate of ($1.44). The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. Leerink Partnrs also issued estimates for Ultragenyx Pharmaceutical's Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.21) EPS, FY2025 earnings at ($5.46) EPS and FY2026 earnings at ($2.83) EPS.

RARE has been the subject of several other reports. Canaccord Genuity Group increased their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a report on Tuesday, February 18th. HC Wainwright reiterated a "buy" rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Morgan Stanley lifted their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the company an "overweight" rating in a research report on Friday. Wedbush reissued a "neutral" rating and issued a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. Finally, JPMorgan Chase & Co. lifted their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $90.93.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock traded up $0.98 during midday trading on Friday, reaching $36.09. The stock had a trading volume of 1,426,573 shares, compared to its average volume of 828,231. The firm's fifty day simple moving average is $36.77 and its two-hundred day simple moving average is $42.24. The firm has a market cap of $3.41 billion, a price-to-earnings ratio of -5.69 and a beta of 0.34. Ultragenyx Pharmaceutical has a twelve month low of $29.59 and a twelve month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The business had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. During the same quarter in the previous year, the firm earned ($2.03) earnings per share. The firm's revenue for the quarter was up 28.0% compared to the same quarter last year.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several large investors have recently made changes to their positions in the stock. Norges Bank acquired a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth about $40,463,000. Vestal Point Capital LP lifted its stake in shares of Ultragenyx Pharmaceutical by 100.0% during the 4th quarter. Vestal Point Capital LP now owns 1,500,000 shares of the biopharmaceutical company's stock worth $63,105,000 after buying an additional 750,000 shares during the last quarter. Deep Track Capital LP bought a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter worth about $27,493,000. Pictet Asset Management Holding SA grew its stake in Ultragenyx Pharmaceutical by 125.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,173,638 shares of the biopharmaceutical company's stock valued at $49,375,000 after buying an additional 653,088 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its stake in Ultragenyx Pharmaceutical by 81.0% in the 4th quarter. Point72 Asset Management L.P. now owns 1,182,877 shares of the biopharmaceutical company's stock valued at $49,764,000 after buying an additional 529,217 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company's stock.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 73,434 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $3,091,571.40. Following the sale, the chief executive officer now directly owns 641,731 shares in the company, valued at $27,016,875.10. The trade was a 10.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $42.88, for a total transaction of $128,211.20. Following the transaction, the executive vice president now directly owns 54,991 shares of the company's stock, valued at $2,358,014.08. This represents a 5.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 125,405 shares of company stock worth $5,285,169. 5.50% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.